Bone marrow (BM) cells were harvested from femur and tibiae of 6–9 week-old CD11c-DTR or CD11c-DTR Rag2-/- SJL mice and depleted of T cells using anti-CD3 and anti-CD8 magnetic beads according to the manufacturer’s instructions (Miltenyi Biotec). Wild type or Rag2-/- SJL mice were gamma-irradiated with 950 rads from a 60Co source. The next day, irradiated mice were injected with T cell-depleted bone marrow cells (5–8 × 106 cells/mouse) pooled from two to three donor mice. The recipient mice were maintained on water containing 1.5% (v/v) sulfamethoxazole/trimethoprim (200 mg/40 mg per 5 ml; Halo Pharmaceutical) for two weeks. They were analyzed for successful engraftment six to eight weeks after reconstitution before being used for experiments.
Anti cd3 and anti cd8 magnetic beads
Manufactured by Miltenyi Biotec
Anti-CD3 and anti-CD8 magnetic beads are a laboratory tool designed for the isolation and enrichment of T cells expressing the CD3 and CD8 surface markers. These beads are superparamagnetic and can be used to selectively bind and separate the target cell populations from heterogeneous samples, such as peripheral blood mononuclear cells, using magnetic separation techniques.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using anti cd3 and anti cd8 magnetic beads
1
Establishment of Humanized Mouse Model
2
Hematopoietic Reconstitution in Irradiated Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Bone marrow (BM) cells were harvested from femur and tibiae of 6-9 week-old CD11c-DTR or CD11c-DTR Rag2-/-SJL mice and depleted of T cells using anti-CD3 and anti-CD8 magnetic beads according to the manufacturer's instructions (Miltenyi Biotec). Wild type or Rag2-/-SJL mice were gamma-irradiated with 950 rads from a 60 Co source. The next day, irradiated mice were injected with T cell-depleted bone marrow cells (5-8 × 10 6 cells/mouse) pooled from two to three donor mice. The recipient mice were maintained on water containing 1.5% (v/v) sulfamethoxazole/trimethoprim (200 mg/40 mg per 5 ml; Halo Pharmaceutical) for two weeks. They were analyzed for successful engraftment six to eight weeks after reconstitution before being used for experiments.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!